Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

ACAAI: Considerable delay seen from Rx to approval for children's biologics

Just now November 17, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

This article discusses delays in biologic therapy approval for pediatric patients in the United States, with nearly 40% of prescriptions being denied during prior authorization. This is not related to Iran and has no direct relevance to Iranian affairs.

There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →